Abstract
Physical interactions among proteins constitute the backbone of cellular function, making them an attractive source of therapeutic targets. Although the challenges associated with targeting protein-protein interactions (PPIs) -in particular with small molecules - are considerable, a growing number of functional PPI modulators is being reported and clinically evaluated. An essential starting point for PPI inhibitor screening or design projects is the generation of a detailed map of the human interactome and the interactions between human and pathogen proteins. Different routes to produce these biological networks are being combined, including literature curation and computational methods. Experimental approaches to map PPIs mainly rely on the yeast two-hybrid (Y2H) technology, which have recently shown to produce reliable protein networks. However, other genetic and biochemical methods will be essential to increase both coverage and resolution of current protein networks in order to increase their utility towards the identification of novel disease-related proteins and PPIs, and their potential use as therapeutic targets.
Keywords: Protein-protein interaction, interactome, drug discovery, small molecule, oncology, virology, PPI modulators, PPI inhibitor, pathogen proteins, yeast two-hybrid (Y2H) technology.
Current Pharmaceutical Design
Title:Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Volume: 18 Issue: 30
Author(s): Jennyfer Bultinck, Sam Lievens and Jan Tavernier
Affiliation:
Keywords: Protein-protein interaction, interactome, drug discovery, small molecule, oncology, virology, PPI modulators, PPI inhibitor, pathogen proteins, yeast two-hybrid (Y2H) technology.
Abstract: Physical interactions among proteins constitute the backbone of cellular function, making them an attractive source of therapeutic targets. Although the challenges associated with targeting protein-protein interactions (PPIs) -in particular with small molecules - are considerable, a growing number of functional PPI modulators is being reported and clinically evaluated. An essential starting point for PPI inhibitor screening or design projects is the generation of a detailed map of the human interactome and the interactions between human and pathogen proteins. Different routes to produce these biological networks are being combined, including literature curation and computational methods. Experimental approaches to map PPIs mainly rely on the yeast two-hybrid (Y2H) technology, which have recently shown to produce reliable protein networks. However, other genetic and biochemical methods will be essential to increase both coverage and resolution of current protein networks in order to increase their utility towards the identification of novel disease-related proteins and PPIs, and their potential use as therapeutic targets.
Export Options
About this article
Cite this article as:
Bultinck Jennyfer, Lievens Sam and Tavernier Jan, Protein-protein Interactions: Network Analysis and Applications in Drug Discovery, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651562
DOI https://dx.doi.org/10.2174/138161212802651562 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews The Effect of Chronic Co-Administration of Morphine and Verapamil on Isoproterenol-Induced Heart Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
Current Alzheimer Research Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)
Recent Patents on Cardiovascular Drug Discovery Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design Recent Advances in the Scaffold Engineering of Protein Binders
Current Pharmaceutical Biotechnology Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Overview and Developments Regarding Functional Foods and Beverages
Current Nutrition & Food Science